UEMS ACCREDITATION



The Course in **THE ROLE OF DYSLIPIDAEMIAS IN DETERMINING CARDIOVASCULAR RISK: FROM LIFESTYLE TO PHARMACOLOGICAL INTERVENTION** is under accreditation by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

EAS have independently organised all matters related to this Programme, including content and presenters.



INTERNATIONAL WORKSHOP

THE ROLE OF DYSLIPIDAEMIAS IN DETERMINING CARDIOVASCULAR RISK: FROM LIFESTYLE TO PHARMACOLOGICAL INTERVENTION

Naples - 2018, November 17-18 - Hotel Royal Continental

Chairs A.L. Catapano, P. Perrone Filardi and L. Tokgözoğlu





ITALIAN ACCREDITATION



CME Provider SITeCS - Società Italiana di Terapia Clinica e Sperimentale Provider Standard Nazionale Via Balzaretti, 7 - 20133 Milano - Tel. +39 02 49636373 e-mail: ecm@sitecs.it - www.sitecs.it

The Congress has been accredited by the National Commission for Continuing Education with the educational objective: Clinical Documentation, Clinical Training-Assistance Diagnostics And Rehabilitation, Assistance Profiles – Care Profiles (3), for the following disciplinary areas: Medical Surgeon (All the disciplines) for 190 participants. The assignment of CME credits will be subject to effective participation in the entire programme, the verification of learning and the detection of presences. The certificate of participation showing the number of credits will be sent by e-mail to the participant after these checks.

CME credits: 7 - CME ID 200-238098 - ed.1

Organizing Secretariat: Delos Communication srl p.co Comola Ricci, 98 - 80122 Naples Tel: +39 081 7142129; Fax: +39 081 7141472 e-mail: info@deloscommunication.it – www.deloscommunication.it

The programme was made possible thanks to an unrestricted educational grant from



		November 17, 2018	17.00	Discussion
C	9.00	REGISTRATION	17.15	COFFEE BREAK
	INTRODUCTION AND SCOPE OF THE MEETING		LIPID-LOWERING GUIDELINES: PRESENT AND FUTURE CHALLENGES	
1	0.30	Introduction and scope of the meeting Alberico L. Catapano - Milan - Italy Pasquale Perrone Filardi - Naples - Italy	17.45	Round Table Chairs and faculty
		Lale Tokgözoğlu - Ankara - Turkey	18.30	Take home messages from the day Lale Tokgözoğlu - Turkey
WHAT TO DO BEFORE INITIATING PHARMACOLOGICAL THERAPY				Luie Tokyozogiu - Turkey
1	1.00	Lifestyle interventions Bernhard Föger - Austria		November 18, 2018
1	11.30	Role of nutraceuticals	FAMILIAL DYS	LIPIDAEMIAS AND VERY HIGH RISK PATIENTS
1	2.00	Matteo Pirro - Italy Discussion	08.30	FH detection and treatment Gerald Watts - Australia
	2.30	LUNCH	09.00	The very high risk patients Alberto Zambon - Italy
			09.30	Discussion
	ATHEROGENIC DYSLIPIDAEMIAS		INTERACTIVE SESSION: ANSWERS FROM THE PARTICIPANTS	
1.	13.45	HDL Maciej Banach - Poland	09.45	Introduction to the interactive session: televoting questions and answers Lale Tokgözoğlu - Turkey
1.	4.15	TG/NON-HDL-C Brian Ference - United Kingdom	09.45	
1.	4.45	Addressing residual CV risk Alberto Zambon - Italy	10.15	Counseling and lifestyle intervention: people at moderate risk
1.	5.15	Discussion	10.45	Catriona Jennings – United Kingdom
	ACHIEVING LDL-C GOALS IN HIGH AND VERY HIGH RISK PATIENTS		10.45	Adherence and persistence to therapy: high CV risk patients Lluis Masana - Spain
1.	5.30	Statins Eric Bruckert - France	11.15	The "Metabolic Syndrome" patients Arrigo Cicero - Italy Closing remarks and take home messages
1	5.00	Ezetimibe and combination therapy Lluis Masana - Spain	11.45	
10	5.30	PCSK9 inhibitors Gerald Watts - Australia	12.00	Alberico L. Catapano - Italy End of the Meeting